Results 161 to 170 of about 107,280 (285)

Targeting the CMKLR1‐Mediated Signaling Rebalances Immunometabolism State in Middle‐Age Testicular Macrophages

Advanced Science, EarlyView.
In middle age, testicular CMKLR1⁺ macrophages exhibited a pro‐inflammatory immunometabolic profile, mediated by adipose signals associated with high BMI. However, inhibition of CMKLR1 signaling, either through Cmklr1 genetic ablation or treatment with a CMKLR1 antagonist peptide, can reverse this phenotype.
Zhendong Zhu, Feifei Du, Yang Liu, Jinchunzi Yang, Lei Ge, Tianxia Xiao, Mengxia Li, Jie Chen, Jia Tang, Yali Yang, Jian V. Zhang   +10 more
wiley   +1 more source

Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy? [PDF]

Int J Mol Sci
Tarjányi O, Olasz K, Rátky F, Sétáló G, Boldizsár F.   +4 more
europepmc   +1 more source

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells. [PDF]

Pharmaceuticals (Basel), 2023
Matsushita M, Kashiwazaki S, Kamiko S, Kobori M, Osada M, Kunieda H, Hirao M, Ichikawa D, Hattori Y.   +8 more
europepmc   +1 more source

Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents

, 2022
Carlos Viera, Bradley T. Stevens, Talysa Viera, Cameron Zielinski, Lee A. Uranga, Snezna Rogelj, Praveen Patidar, Rodolfo Tello‐Aburto   +7 more
openalex   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

ChaC1-based drug screenings identify a synergistic lethal effect of auranofin and proteasome inhibitors in hepatocellular carcinoma cells. [PDF]

Cell Death Discov
Yu C, Liu J, Jian H, Wen B, Jiang M, Zhang B, Lin M, Lin J, Dai Z, Zhong CQ, Zheng M.   +10 more
europepmc   +1 more source

Brd4 BD1 Domain Antagonism of MS436 Preserves Blood‐Brain Barrier Integrity via Rnf43/β‐Catenin Signaling Pathway

Advanced Science, EarlyView.
MS436 competitively binds to the BD1 domain of Brd4, thereby suppressing Brd4 induced degradation of tight junction proteins via the Rnf43‐Fzd4‐β‐catenin signaling pathway. Consequently, this attenuation of degradation reduces blood‐brain barrier leakage, leading to an improved overall prognosis after stroke.
Chenxiao Li, Xiaochen Zhang, Jiangwei Xia, Shuang Liu, Yushan Du, Sihan Li, Shukui Zhang, Yong Zhang, Fen Ji, Jianwei Jiao, Jingjing Zhang   +10 more
wiley   +1 more source

Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma. [PDF]

Clin Exp Med
Sedlacek J.
europepmc   +1 more source

The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma. [PDF]

Blood Adv, 2023
Findlay S, Nair R, Merrill RA, Kaiser Z, Cajelot A, Aryanpour Z, Heath J, St-Louis C, Papadopoli D, Topisirovic I, St-Pierre J, Sebag M, Kesarwala AH, Hulea L, Taylor EB, Shanmugam M, Orthwein A.   +16 more
europepmc   +1 more source

Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies [PDF]

, 2010
Enrica Marchi, Luca Paoluzzi, Luigi Scotto, Venkatraman Seshan, Jasmine Zain, Pier Luigi Zinzani, Owen A. O’Connor   +6 more
openalex   +1 more source